The fact sheet library
Search by name, alias, category, approval status, or evidence level. Each fact sheet puts the quick answer and the unknowns up front.
Showing 35 of 35 fact sheets
Status, evidence, and unknowns on every page
A GLP-1 medicine with FDA-approved products for type 2 diabetes and chronic weight management.
A dual GIP/GLP-1 receptor agonist approved for specific metabolic and sleep-apnea uses.
An investigational triple-receptor agonist in Phase 3 clinical trials.
An established GLP-1 medicine approved for specific diabetes and weight-management uses.
A growth hormone-releasing factor analog approved for a narrow HIV-related indication.
A growth hormone-releasing hormone analog whose former FDA-approved product was discontinued.
An unapproved growth hormone-releasing hormone analog with limited human data.
An unapproved growth hormone secretagogue with limited clinical evidence and FDA-identified concerns.
An experimental synthetic peptide popular online despite very limited reliable human evidence.
A naturally occurring peptide studied in tissue repair; marketed fragments are not FDA approved.
A mitochondria-targeting peptide with an accelerated FDA approval for a narrow Barth syndrome indication.
A natural peptide hormone with approved obstetric products and unproven intranasal cognitive or social uses.
A reproductive signaling peptide studied in fertility, hormone release, and brain responses.
A melanocortin-receptor peptide approved for a narrowly defined sexual-desire disorder.
A cone-snail-inspired peptide medicine approved for severe chronic pain under specialist care.
An MC4-receptor peptide medicine approved for obesity caused by specific rare genetic conditions.
A C-type natriuretic peptide analog approved to increase growth in children with achondroplasia.
An investigational hepcidin-mimetic peptide under FDA priority review for polycythemia vera.
An unapproved neuroactive heptapeptide with old, small human studies and substantial evidence gaps.
An unapproved synthetic heptapeptide studied for anxiety, with a thin and uncertain human evidence base.
A mitochondrial-derived peptide with intriguing metabolic and exercise biology but no proven human therapy.
A mitochondrial-derived peptide studied for cell survival, neuroprotection, metabolism, and aging mostly in preclinical work.
A copper-binding tripeptide used in cosmetic research, with mostly laboratory and animal wound-healing evidence.
An unapproved ghrelin-receptor agonist that raises growth hormone and appetite without proven muscle-building outcomes.
An immune-modulating peptide used in some countries but not FDA approved for any U.S. indication.
An FDA-approved synthetic peptide analog for Rett syndrome with modest trial benefits and frequent gastrointestinal adverse effects.
An FDA-approved amylin analog for selected insulin-treated diabetes patients, with unapproved weight-management research.
An investigational long-acting amylin analog studied alone and with semaglutide for obesity and type 2 diabetes.
An investigational glucagon/GLP-1 dual agonist in Phase 3 research for obesity and metabolic liver disease.
An investigational glucagon/GLP-1 dual agonist in mid-stage research for MASH, liver fat, and obesity.
An FDA-approved GLP-2 analog that improves intestinal absorption in short bowel syndrome dependent on parenteral support.
A minimally absorbed peptide medicine approved for several constipation disorders in defined adult and pediatric populations.
An FDA-approved gut-signaling peptide for chronic idiopathic constipation and IBS with constipation in adults.
A discontinued U.S. GLP-1 product with established diabetes evidence and an encouraging but unconfirmed Parkinson trial.
An FDA-approved diabetes peptide whose promising Phase 2 Parkinson signal failed in a larger Phase 3 trial.